

LITERATURVERZEICHNIS

- Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ and Davis MM (1996). "Phenotypic analysis of antigen-specific T lymphocytes." Science **274**(5284): 94-6.
- Alwan WH, Kozlowska WJ and Openshaw PJ (1994). "Distinct types of lung disease caused by functional subsets of antiviral T cells." J Exp Med **179**(1): 81-9.
- Atkinson K, Arthur C, Bradstock K, Dale B, Downs K, Gibson J, Golenia M, Ho J, Joshua D, Juttner C and et al. (1995). "Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group." Bone Marrow Transplant **16**(3): 401-5.
- Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D and Levy F (2002). "Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma." J Immunol **168**(4): 1717-22.
- Badley AD, Portela DF, Patel R, Kyle RA, Habermann TM, Strickler JG, Ilstrup DM, Wiesner RH, de Groen P, Walker RC and Paya CV (1996). "Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder." Liver Transpl Surg **2**(5): 375-82.
- Banchereau J and Steinman RM (1998). "Dendritic cells and the control of immunity." Nature **392**(6673): 245-52.
- Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ and Blankenstein T (2001). "Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay." Nat Med **7**(10): 1159-62.
- Berencsi K, Gyulai Z, Gonczol E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M, Zahradnik J, Starr S and Plotkin S (2001). "A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects." J Infect Dis **183**(8): 1171-9.
- Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, Koup RA and Picker LJ (2001). "Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection." J Virol **75**(24): 11983-91.
- Betts MR, Casazza JP, Patterson BA, Waldrop S, Trigona W, Fu TM, Kern F, Picker LJ and Koup RA (2000). "Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype." J Virol **74**(19): 9144-51.
- Biron CA, Nguyen KB, Pien GC, Cousens LP and Salazar-Mather TP (1999). "Natural killer cells in antiviral defense: function and regulation by innate cytokines." Annu Rev Immunol **17**: 189-220.

- Biron CA, Young HA and Kasaian MT (1990). "Interleukin 2-induced proliferation of murine natural killer cells in vivo." *J Exp Med* **171**(1): 173-88.
- Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S and Gress R (2004). "Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer." *J Clin Oncol* **22**(19): 3886-92.
- Bissinger AL, Rauser G, Hebart H, Frank F, Jahn G and Einsele H (2002). "Isolation and expansion of human cytomegalovirus- specific cytotoxic T lymphocytes using interferon-gamma secretion assay." *Exp Hematol* **30**(10): 1178-84.
- Boeckh M (1996a). American Society of Hematology 38th Annual Meeting, Orlando, Florida.
- Boeckh M, Bowden RA, Goodrich JM, Pettinger M and Meyers JD (1992). "Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation." *Blood* **80**(5): 1358-64.
- Boeckh M, Bowden RA, Gooley T, Myerson D and Corey L (1999). "Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients." *Blood* **93**(5): 1781-2.
- Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G and Bowden RA (1996b). "Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study." *Blood* **88**(10): 4063-71.
- Boeckh M, Stevens-Ayers T and Bowden RA (1996c). "Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation." *J Infect Dis* **174**(5): 907-12.
- Boeckh ML, P (1998). *Cytomegalovirus infection after bone marrow transplantation*. Philadelphia, Lippencott-Raven.
- Bolland CM, Kuehnle I, Leen A, Rooney CM and Heslop HE (2004). "Adoptive immunotherapy for posttransplantation viral infections." *Biol Blood Marrow Transplant* **10**(3): 143-55.
- Borysiewicz LK, Graham S, Hickling JK, Mason PD and Sissons JG (1988). "Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity." *Eur J Immunol* **18**(2): 269-75.
- Bourgault I, Gomez A, Gomard E and Levy JP (1991). "Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes." *Clin Exp Immunol* **84**(3): 501-7.
- Bourgeois C, Rocha B and Tanchot C (2002). "A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory." *Science* **297**(5589): 2060-3.
- Bowden RA, Digel J, Reed EC and Meyers JD (1987). "Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses." *J Infect Dis* **156**(6): 899-903.
- Bowen EF, Griffiths PD, Davey CC, Emery VC and Johnson MA (1996a). "Lessons from the natural history of cytomegalovirus." *Aids* **10 Suppl 1**: S37-41.

- Bowen EF, Wilson P, Cope A, Sabin C, Griffiths P, Davey C, Johnson M and Emery V (1996b). "Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival." *Aids* **10**(13): 1515-20.
- Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, Greenberg PD and Riddell SR (1999). "In vivo migration and function of transferred HIV-1-specific cytotoxic T cells." *Nat Med* **5**(1): 34-41.
- Brusic V, Rudy G and Harrison LC (1998a). "MHCPEP, a database of MHC-binding peptides: update 1997." *Nucleic Acids Res* **26**(1): 368-71.
- Brusic V, Rudy G, Honeyman G, Hammer J and Harrison L (1998b). "Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network." *Bioinformatics* **14**(2): 121-30.
- Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkohl H and Kern F (2005). "Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells." *J Exp Med* **201**(7): 1031-6.
- Burmester G-R, Pezutto A. (1998). *Taschenatlas der Immunologie*. Stuttgart, Thieme-Verlag.
- Cheever MA, Greenberg PD, Fefer A and Gillis S (1982). "Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2." *J Exp Med* **155**(4): 968-80.
- Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL, Stanat SC and Biron KK (1995a). "Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance." *J Infect Dis* **171**(3): 576-83.
- Chou S, Guentzel S, Michels KR, Miner RC and Drew WL (1995b). "Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates." *J Infect Dis* **172**(1): 239-42.
- de Jong MD, Galasso GJ, Gazzard B, Griffiths PD, Jabs DA, Kern ER and Spector SA (1998). "Summary of the II International Symposium on Cytomegalovirus." *Antiviral Res* **39**(3): 141-62.
- Delecluse HJ, Pich D, Hilsendegen T, Baum C and Hammerschmidt W (1999). "A first-generation packaging cell line for Epstein-Barr virus-derived vectors." *Proc Natl Acad Sci U S A* **96**(9): 5188-93.
- DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG and Snyderman DR (1998). "Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection." *J Infect Dis* **178**(6): 1783-6.
- Dhodapkar MV and Bhardwaj N (2000). "Active immunization of humans with dendritic cells." *J Clin Immunol* **20**(3): 167-74.
- Diamond DJ, York J, Sun JY, Wright CL and Forman SJ (1997). "Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection." *Blood* **90**(5): 1751-67.

Docke WD, Prosch S, Fietze E, Kimel V, Zuckermann H, Klug C, Syrbe U, Kruger DH, von Baehr R and Volk HD (1994). "Cytomegalovirus reactivation and tumour necrosis factor." *Lancet* **343**(8892): 268-9.

Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzenruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF and Rosenberg SA (2001). "Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma." *J Immunother* **24**(4): 363-73.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzenruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE and Rosenberg SA (2002). "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes." *Science* **298**(5594): 850-4.

Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, Klingebiel T, Dietz K, Loeffler J, Bokemeyer C, Muller CA and Kanz L (2000). "Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection." *Bone Marrow Transplant* **25**(7): 757-63.

Einsele H, Herbart H, Bock T, Muller C, Fleckenstein B, Mach M, Stamminger T, Jahn G, Sinzger C, Koszinowski U, Meyer-Konig U, Mertens T, Plachter B, Reddehase MJ and Schmidt CA (1999). "[Recommendations for the diagnosis and therapy of cytomegalovirus infection after stem-cell transplantation. The Research Alliance on the Complications of Organ Transplantation due to Herpes Viruses]." *Dtsch Med Wochenschr* **124**(16): 501-6.

Einsele H, Rauser G, Grigoleit U, Hebart H, Sinzger C, Riegler S and Jahn G (2002a). "Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide." *Cytotherapy* **4**(1): 49-54.

Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loeffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G and Hebart H (2002b). "Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy." *Blood* **99**(11): 3916-22.

Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M and Khanna R (2003). "Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers." *J Virol* **77**(9): 5226-40.

Fields BN, Knipe DM and Howley PM (1995). *Virology*, Lippincott-Raven Publishers, Philadelphia, New York.

Fishman JA and Rubin RH (1998). "Infection in organ-transplant recipients." *N Engl J Med* **338**(24): 1741-51.

Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi S, Burke RL and Duliege AM (1999). "Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine." *J Infect Dis* **180**(5): 1700-3.

George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN and Rubin RH (1997). "The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation

CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland." Am J Med **103**(2): 106-13.

Gilbert MJ, Riddell SR, Li CR and Greenberg PD (1993). "Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus." J Virol **67**(6): 3461-9.

Gilbert MJ, Riddell SR, Plachter B and Greenberg PD (1996). "Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product." Nature **383**(6602): 720-2.

Glenn J (1981). "Cytomegalovirus infections following renal transplantation." Rev Infect Dis **3**(6): 1151-78.

Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G and Meyers JD (1993). "Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant." Ann Intern Med **118**(3): 173-8.

Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE and Rooney CM (2001). "An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs." Blood **97**(4): 835-43.

Graham MB, Braciale VL and Braciale TJ (1994). "Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection." J Exp Med **180**(4): 1273-82.

Grakoui A, Shoukry NH, Woppard DJ, Han JH, Hanson HL, Ghayeb J, Murthy KK, Rice CM and Walker CM (2003). "HCV persistence and immune evasion in the absence of memory T cell help." Science **302**(5645): 659-62.

Greenberg PD, Cheever MA and Fefer A (1982). "Specific adoptive immunotherapy: experimental basis and future potential." Surv Immunol Res **1**(1): 85-90.

Greenberg PD and Riddell SR (1999). "Deficient cellular immunity--finding and fixing the defects." Science **285**(5427): 546-51.

Gyulai Z, Endresz V, Burian K, Pincus S, Toldy J, Cox WI, Meric C, Plotkin S, Gonczol E and Berencsi K (2000). "Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs." J Infect Dis **181**(5): 1537-46.

Hammer D (2004). mündliche Mitteilung. Institut für Medizinische Immunologie, Charité, Berlin.

Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK and Rooney CM (1996). "Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes." Nat Med **2**(5): 551-5.

Ho M (1994). "Advances in understanding cytomegalovirus infection after transplantation." Transplant Proc **26**(5 Suppl 1): 7-11.

Ho WY, Yee C and Greenberg PD (2002). "Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends." J Clin Invest **110**(10): 1415-7.

- Hunziker L, Klenerman P, Zinkernagel RM and Ehl S (2002). "Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells." *Eur J Immunol* **32**(2): 374-82.
- Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T and Ohno T (2004). "Autologous natural killer cell therapy for human recurrent malignant glioma." *Anticancer Res* **24**(3b): 1861-71.
- Janeway CA (2005). *Immunobiology. The Immune System in Health and Disease*. Garland, Garland Science Publishing.
- Kalams SA and Walker BD (1998). "The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses." *J Exp Med* **188**(12): 2199-204.
- Keenan RD, Ainsworth J, Khan N, Bruton R, Cobbold M, Assenmacher M, Milligan DW and Moss PA (2001). "Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers." *Br J Haematol* **115**(2): 428-34.
- Kempkes B, Pich D, Zeidler R and Hammerschmidt W (1995a). "Immortalization of human primary B lymphocytes in vitro with DNA." *Proc Natl Acad Sci U S A* **92**(13): 5875-9.
- Kempkes B, Pich D, Zeidler R, Sugden B and Hammerschmidt W (1995b). "Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA." *J Virol* **69**(1): 231-8.
- Kern F, Bunde T, Faulhaber N, Kiecker F, Khatamzas E, Rudawski IM, Pruss A, Gratama JW, Volkmer-Engert R, Ewert R, Reinke P, Volk HD and Picker LJ (2002). "Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals." *J Infect Dis* **185**(12): 1709-16.
- Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schonemann C, Kretzschmar I, Volkmer-Engert R, Volk HD and Reinke P (2000). "Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides." *Eur J Immunol* **30**(6): 1676-82.
- Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P and Volk HD (1998). "T-cell epitope mapping by flow cytometry." *Nat Med* **4**(8): 975-8.
- Kern F, Surel IP, Faulhaber N, Frommel C, Schneider-Mergener J, Schonemann C, Reinke P and Volk HD (1999). "Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited." *J Virol* **73**(10): 8179-84.
- Khan N, Cobbold M, Keenan R and Moss PA (2002). "Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype." *J Infect Dis* **185**(8): 1025-34.
- Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L, Clarke B, Slaughter R, Falk MC, Douglass J, Williams T, Elliott SL and Moss DJ (1999). "Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease." *Proc Natl Acad Sci U S A* **96**(18): 10391-6.

Khong HT, Wang QJ and Rosenberg SA (2004). "Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression." J Immunother **27**(3): 184-90.

Kleihauer A, Grigoleit U, Hebart H, Moris A, Brossart P, Muhs A, Stevanovic S, Rammensee HG, Sinzger C, Rieger S, Jahn G, Kanz L and Einsele H (2001). "Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells." Br J Haematol **113**(1): 231-9.

Klingemann HG (2000). "Relevance and potential of natural killer cells in stem cell transplantation." Biol Blood Marrow Transplant **6**(2): 90-9.

Knutson KL, Almand B, Mankoff DA, Schiffman K and Disis ML (2002). "Adoptive T-cell therapy for the treatment of solid tumours." Expert Opin Biol Ther **2**(1): 55-66.

Köhler WE, H.J.; Fleischer, B.; Marre R.; Pfister, H.; Pulverer G.; (2001). Medizinische Mikrobiologie. München, Urban & Fischer Verlag.

Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M and Wilmanns W (1990). "Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients." Blood **76**(12): 2462-5.

Krause H, Hebart H, Jahn G, Muller CA and Einsele H (1997). "Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease." Bone Marrow Transplant **19**(11): 1111-6.

Kyburz D, Speiser DE, Aebscher T, Hengartner H and Zinkernagel RM (1993). "Virus-specific cytotoxic T cell-mediated lysis of lymphocytes in vitro and in vivo." J Immunol **150**(11): 5051-8.

Lamberson HV and Dock NL (1992). "Prevention of transfusion-transmitted cytomegalovirus infection." Transfusion **32**: 196.

Larsson S, Soderberg-Naucler C and Moller E (1998). "Productive cytomegalovirus (CMV) infection exclusively in CD13-positive peripheral blood mononuclear cells from CMV-infected individuals: implications for prevention of CMV transmission." Transplantation **65**(3): 411-5.

Lewis RM, Janney RP, Van Buren CT, Kerman RH, Herson J, Kerr NA, Golden DA and Kahan BD (1988). "A retrospective analysis of long-term renal allograft function associated with cyclosporine-prednisone immunosuppressive therapy." Transplant Proc **20**(3 Suppl 3): 534-9.

Li CR, Greenberg PD, Gilbert MJ, Goodrich JM and Riddell SR (1994). "Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis." Blood **83**(7): 1971-9.

Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, Cordonnier C, Debusscher L, de Laurenzi A, Kolb HJ and et al. (1992). "Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group." Clin Infect Dis **14**(4): 831-5.

Ljungman P, Gleaves CA and Meyers JD (1989). "Respiratory virus infection in immunocompromised patients." Bone Marrow Transplant **4**(1): 35-40.

- Ma Q, Safar M, Holmes E, Wang Y, Boynton AL and Junghans RP (2004). "Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy." *Prostate* **61**(1): 12-25.
- Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F and Picker LJ (2001). "Use of overlapping peptide mixtures as antigens for cytokine flow cytometry." *J Immunol Methods* **255**(1-2): 27-40.
- Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, Dummer S and Ho M (1997). "Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease." *J Infect Dis* **176**(6): 1462-7.
- Manley TJ, Luy L, Jones T, Boeckh M, Mutimer H and Riddell SR (2004). "Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection." *Blood* **104**(4): 1075-82.
- Manz R, Assenmacher M, Pfluger E, Miltenyi S and Radbruch A (1995). "Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix." *Proc Natl Acad Sci U S A* **92**(6): 1921-5.
- Matloubian M, Concepcion RJ and Ahmed R (1994). "CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection." *J Virol* **68**(12): 8056-63.
- McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD and Riddell SR (1994). "Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes." *J Med Virol* **43**(1): 103-10.
- Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R and Mackensen A (2003). "Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients." *J Immunol* **170**(4): 2161-9.
- Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM and et al. (1992). "A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation." *N Engl J Med* **326**(18): 1182-6.
- Midgley RS, Bell AI, Yao QY, Croom-Carter D, Hislop AD, Whitney BM, Chan AT, Johnson PJ and Rickinson AB (2003). "HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences." *J Virol* **77**(21): 11507-16.
- Moosmann A, Khan N, Cobbold M, Zentz C, Delecluse HJ, Hollweck G, Hislop AD, Blake NW, Croom-Carter D, Wollenberg B, Moss PA, Zeidler R, Rickinson AB and Hammerschmidt W (2002). "B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells." *Blood* **100**(5): 1755-64.
- Moreso F, Seron D, Morales JM, Cruzado JM, Gil-Vernet S, Perez JL, Fulladosa X, Andres A and Grinyo JM (1998). "Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses." *Clin Transplant* **12**(3): 198-205.

- Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL (1986). "Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins." J Immunol **136**(7): 2348-57.
- Moutaftsi M, Mehl AM, Borysiewicz LK and Tabi Z (2002). "Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells." Blood **99**(8): 2913-21.
- Movassagh M, Gozlan J, Senechal B, Baillou C, Petit JC and Lemoine FM (1996). "Direct infection of CD34+ progenitor cells by human cytomegalovirus: evidence for inhibition of hematopoiesis and viral replication." Blood **88**(4): 1277-83.
- Oelke M, Maus MV, Didiano D, June CH, Mackensen A and Schneck JP (2003). "Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells." Nat Med **9**(5): 619-24.
- Oelke M, Moehrle U, Chen JL, Behringer D, Cerundolo V, Lindemann A and Mackensen A (2000). "Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy." Clin Cancer Res **6**(5): 1997-2005.
- Oldstone MB (1997). "How viruses escape from cytotoxic T lymphocytes: molecular parameters and players." Virology **234**(2): 179-85.
- Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN and et al. (1994). "Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation." N Engl J Med **330**(17): 1185-91.
- Parker KC, Bednarek MA and Coligan JE (1994). "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains." J Immunol **152**(1): 163-75.
- Paya CV, Wiesner RH, Hermans PE, Larson-Keller JJ, Ilstrup DM, Krom RA, Rettke S and Smith TF (1993). "Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis." J Hepatol **18**(2): 185-95.
- Peggs K, Verfuerth S and Mackinnon S (2001). "Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions." Blood **97**(4): 994-1000.
- Peggs KS, Verfuerth S, Pizsey A, Khan N, Guiver M, Moss PA and Mackinnon S (2003). "Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines." Lancet **362**(9393): 1375-7.
- Ploegh HL (1998). "Viral strategies of immune evasion." Science **280**(5361): 248-53.
- Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, Krom RA and Paya CV (1995). "OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation." J Infect Dis **171**(4): 1014-8.
- Quinnan GV, Jr., Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Saral R and Burns WH (1982). "Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with

recovery from cytomegalovirus infection in bone-marrow-transplant recipients." *N Engl J Med* **307**(1): 7-13.

Rammensee H, Bachmann J, Emmerich NP, Bachor OA and Stevanovic S (1999). "SYFPEITHI: database for MHC ligands and peptide motifs." *Immunogenetics* **50**(3-4): 213-9.

Ratnamohan VM, Chapman J, Howse H, Bovington K, Robertson P, Byth K, Allen R and Cunningham AL (1998). "Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation." *Transplantation* **66**(7): 877-82.

Reddehase MJ, Mutter W and Koszinowski UH (1987a). "In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection." *J Exp Med* **165**(3): 650-6.

Reddehase MJ, Mutter W, Munch K, Buhring HJ and Koszinowski UH (1987b). "CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity." *J Virol* **61**(10): 3102-8.

Reddehase MJ, Weiland F, Munch K, Jonjic S, Luske A and Koszinowski UH (1985). "Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs." *J Virol* **55**(2): 264-73.

Reinke P, Fietze E, Ode-Hakim S, Prosch S, Lippert J, Ewert R and Volk HD (1994). "Late-acute renal allograft rejection and symptomless cytomegalovirus infection." *Lancet* **344**(8939-8940): 1737-8.

Reinke P, Prosch S, Kern F and Volk HD (1999). "Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients." *Transpl Infect Dis* **1**(3): 157-64.

Retiere C, Prod'homme V, Imbert-Marcille BM, Bonneville M, Vie H and Hallet MM (2000). "Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response." *J Virol* **74**(9): 3948-52.

Reusser P, Riddell SR, Meyers JD and Greenberg PD (1991). "Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease." *Blood* **78**(5): 1373-80.

Riddell SR and Greenberg PD (1994). "Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones." *Curr Top Microbiol Immunol* **189**: 9-34.

Riddell SR and Greenberg PD (1997). "T cell therapy of human CMV and EBV infection in immunocompromised hosts." *Rev Med Virol* **7**(3): 181-192.

Riddell SR, Rabin M, Geballe AP, Britt WJ and Greenberg PD (1991). "Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression." *J Immunol* **146**(8): 2795-804.

Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME and Greenberg PD (1992). "Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones." *Science* **257**(5067): 238-41.

Ridolfi L, Ridolfi R, Riccobon A, De Paola F, Petrini M, Stefanelli M, Flamini E, Ravaioli A, Verdecchia GM, Trevisan G and Amadori D (2003). "Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma." J Immunother **26**(2): 156-62.

Ringden O, Pihlstedt P, Volin L, Nikoskelainen J, Lonnqvist B, Ruutu P, Ruutu T, Toivanen A and Wahren B (1987). "Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group." Bone Marrow Transplant **2**(3): 299-305.

Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK and Heslop HE (1995). "Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation." Lancet **345**(8941): 9-13.

Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK and Heslop HE (1998). "Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients." Blood **92**(5): 1549-55.

Rosen FS, Cooper MD and Wedgwood RJ (1984). "The primary immunodeficiencies (1)." N Engl J Med **311**(4): 235-42.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT and et al. (1985). "Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer." N Engl J Med **313**(23): 1485-92.

Rubin RH (1990). "Impact of cytomegalovirus infection on organ transplant recipients." Rev Infect Dis **12 Suppl 7**: S754-66.

Rubin RH (2000). "Prevention and treatment of cytomegalovirus disease in heart transplant patients." J Heart Lung Transplant **19**(8): 731-5.

Sageda S, Nordal KP, Hartmann A, Sund S, Scott H, Degre M, Foss A, Leivestad T, Osnes K, Fauchald P and Rollag H (2002). "The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients." Am J Transplant **2**(9): 850-6.

Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE and Rooney CM (2002). "Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals." J Immunol **168**(2): 909-18.

Sia IG and Patel R (2000). "New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients." Clin Microbiol Rev **13**(1): 83-121, table of contents.

Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE and Rooney CM (2003). "Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy." J Immunother **26**(3): 241-56.

Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, Makowka L, Starzl TE and Ho M (1988). "Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies." J Infect Dis **158**(1): 124-31.

- Smith MA and Brennessel DJ (1994). "Cytomegalovirus." Infect Dis Clin North Am **8**(2): 427-38.
- Snydman DR (1991). "Prevention of cytomegalovirus-associated diseases with immunoglobulin." Transplant Proc **23**(3 Suppl 3): 131-5, discussion 135.
- Solache A, Morgan CL, Dodi AI, Morte C, Scott I, Baboonian C, Zal B, Goldman J, Grundy JE and Madrigal JA (1999). "Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus." J Immunol **163**(10): 5512-8.
- Steffens HP, Kurz S, Holtappels R and Reddehase MJ (1998). "Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence." J Virol **72**(3): 1797-804.
- Subklewe M, Chahroudi A, Schmaljohn A, Kurilla MG, Bhardwaj N and Steinman RM (1999). "Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus." Blood **94**(4): 1372-81.
- Sun Q, Burton RL, Dai LJ, Britt WJ and Lucas KG (2000). "B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen." J Immunol **165**(7): 4105-11.
- Sun Q, Burton RL and Lucas KG (2002). "Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures." Blood **99**(9): 3302-9.
- Sun Q, Pollok KE, Burton RL, Dai LJ, Britt W, Emanuel DJ and Lucas KG (1999). "Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65." Blood **94**(9): 3242-50.
- Szer J, Grigg AP, Phillips GL and Sheridan WP (1993). "Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT." Bone Marrow Transplant **11**(2): 109-11.
- Szmania S, Galloway A, Bruorton M, Musk P, Aubert G, Arthur A, Pyle H, Hensel N, Ta N, Lamb L, Jr., Dodi T, Madrigal A, Barrett J, Henslee-Downey J and van Rhee F (2001). "Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers." Blood **98**(3): 505-12.
- Taylor-Wiedeman J, Sissons JG, Borysiewicz LK and Sinclair JH (1991). "Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells." J Gen Virol **72** (Pt 9): 2059-64.
- Toro AI and Ossa J (1996). "PCR activity of CMV in healthy CMV-seropositive individuals: does latency need redefinition?" Res Virol **147**(4): 233-8.
- Tuma RA, Giannino R, Guirnalda P, Leiner I and Palmer EG (2002). "Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus." J Clin Invest **110**(10): 1493-501.

- Wagner JA, Ross H, Hunt S, Gamberg P, Valentine H, Merigan TC and Stinson EB (1995). "Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation." Transplantation **60**(12): 1473-7.
- Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED and Riddell SR (1995). "Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor." N Engl J Med **333**(16): 1038-44.
- Wiesner M, Zentz C, Hammer MH, Cobbold M, Kern F, Kolb HJ, Hammerschmidt W, Zeidler R and Moosmann A (2005). "Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines." Eur J Immunol **35**(7): 2110-21.
- Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B and Sissons JG (1996). "The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL." J Virol **70**(11): 7569-79.
- Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC and Champlin RE (1993). "Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial." Ann Intern Med **118**(3): 179-84.
- Zaia JA, Gallez-Hawkins GM, Tegtmeier BR, ter Veer A, Li X, Niland JC and Forman SJ (1997). "Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma." J Infect Dis **176**(3): 782-5.
- Zaia JA, Sissons JG, Riddell S, Diamond DJ, Wills MR, Carmichael AJ, Weekes MP, Gandhi M, La Rosa C, Villacres M, Lacey S, Markel S and Sun J (2000). "Status of Cytomegalovirus Prevention and Treatment in 2000." Hematology (Am Soc Hematol Educ Program): 339-355.
- Zajac AJ, Blattman JN, Murali-Krishna K, Sourdice DJ, Suresh M, Altman JD and Ahmed R (1998a). "Viral immune evasion due to persistence of activated T cells without effector function." J Exp Med **188**(12): 2205-13.
- Zajac AJ, Murali-Krishna K, Blattman JN and Ahmed R (1998b). "Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells." Curr Opin Immunol **10**(4): 444-9.
- Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T and Epstein SE (1996). "Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy." N Engl J Med **335**(9): 624-30.
- Zhuravskaya T, Maciejewski JP, Netski DM, Bruening E, Mackintosh FR and St Jeor S (1997). "Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency." Blood **90**(6): 2482-91.